B-Cell Reduction Using CD37-Specific And CD20-Specific Binding Molecules

Details for Australian Patent Application No. 2012203322 (hide)

Owner Emergent Product Development Seattle, LLC

Inventors Ledbetter, Jeffrey A.; Hayden-Ledbetter, Martha S.; Thompson, Peter A.; Grosmaire, Laura Sue; Simon, Sandy Alexander

Agent Wrays

Pub. Number AU-A-2012203322

Parent 2006272555

Filing date 6 June 2012

Wipo publication date 28 June 2012

International Classifications

C07K 16/28 Immunoglobulins, e.g. monoclonal or polyclonal antibodies

A61K 39/395 Medicinal preparations containing antigens or antibodies - Antibodies

A61P 21/04 Drugs for disorders of the muscular or neuromuscular system

A61P 35/00 Antineoplastic agents

A61P 37/00 Drugs for immunological or allergic disorders

C07K 16/46 Immunoglobulins, e.g. monoclonal or polyclonal antibodies - Hybrid immunoglobulins

C12N 5/10 Undifferentiated human, animal or plant cells, e.g. cell lines - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

C12N 15/13 Mutation or genetic engineering - Immunoglobulins

C12N 15/85 Mutation or genetic engineering - for animal cells

Event Publications

21 June 2012 Complete Application Filed

28 June 2012 Application Open to Public Inspection

  Published as AU-A-2012203322

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2012203323-Polymer-factor IX moiety conjugates

2012203321-Communication System